Advanced Therapy Medicinal Products (ATMPs), also known as cell and gene therapies, are becoming increasingly common.  However, they’re far more complex than “traditional” biotech products, with sophisticated requirements throughout their supply chains.  

They must be managed with speed and precision, with stringent biosafety requirements and tightly controlled temperatures, all while protecting patient data, as well as the chains of identity and custody.  This must be done through numerous steps and supply chain partners.

Making an ATMP supply chain work requires precise orchestration.  A biopharma company must ensure that all partners and components “mesh” effectively.  

    This webinar will :
     Identify the unique components that make ATMP supply chains so complex
     Show key points where precise orchestration is needed to prepare supply chains for launch and keep them running smoothly
     Provide guidance for decision makers, who must orchestrate supply chains in an environment with evolving regulatory frameworks and few consistent standards


alt text

Ronald van Zitteren  



Ronald van Zitteren is a Principal with AIM and a member of the firm’s management team. His primary focus is on helping clients design and develop supply chains for new product launches in the EU.  His background in the biopharma industry is extensive.  He was Senior Director of Supply Chain Strategy and Senior Director of Distribution and Logistics at UCB.  Ronald also led pan-EU service teams at UCB, Amgen, and Zeneca.  His educational background includes a BSc in Marketing and Economics.

alt text

Laurent Goux 

Senior Vice President and General Manager, Europe 

Krystal Biotech, Inc.

Laurent Goux is Senior Vice President and General Manager, Europe at Krystal Biotech, Inc.  Laurent’s extensive life science background includes more than 10 years in General Manager roles and functional experience in Finance, Business Development, Marketing, and Market Access.  He has lived and worked in four countries and carried responsibilities across multiple continents.  His education includes master’s degrees in physics, chemistry, and international business.

alt text

Reinout Hesselink Ph.D., R.H.

Cell Therapy Consulting

Reinout Hesselink is a freelance consultant for senior level CMC/QA roles in cell and gene therapy  His professional focus is on CMC and the development of cell and gene therapy production process from early clinical through to commercial products. Reinout has a proven track record as a general manager and in-depth experience preparing for the clinical and commercial supply of cell and gene therapies.  His background includes roles at Lonza, BioNTech, ExCellThera, Cimaas, and Pan Cancer T, as well as consulting for many others.  He earned his PhD at Maastricht University in skeletal muscle damage and regeneration.

alt text

David Kann 

Senior Associate 


David Kann is a Senior Associate with AIM.  His focus is on global product launch and supply chain design and implementation for pharmaceuticals, ATMPs, and medical devices.  He has more than 16 years in life science supply chain and consulting.  Before joining AIM, he served as Head of EU Distribution and Logistics and as Head of Medical Device Supply Chain at Hospira.  He also served as the Supply Chain Planning Lead at Abbott Laboratories. David earned his MSc in mechanical engineering.

Hosted by

Maire Gerrard

Managing Editor, Custom Content

Pharma Intelligence

Complete the form to register for this webinar!

Our presenters will carry out a live Q&A, if you have any questions please let us know.
By ticking this box, you agree to receive emails such as relevant news, updates and offers from Informa Business Intelligence, and carefully selected similar products from our portfolio

By completing this form you agree AIM may contact you directly about industry news, products, services and events that may be of interest to you subject to their privacy policy.